The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
2021 · npj Breast Cancer · 257 citations
https://doi.org/10.1038/s41523-021-00346-1
N
Nils Ternès
Sanofi (France)(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
52
Papers
3.6K
Citations
18
h-index
21
i10-index
Nils Ternès is an academic researcher from Sanofi (France). The author has contributed to research in topics: Statistical Methods and Inference & Gene expression and cancer classification & Cancer Immunotherapy and Biomarkers. The author has an h-index of 18, co-authored 45 publications.
Papers by this author
worksSpontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought
2013 · Annals of Surgical Oncology · 231 citations
https://doi.org/10.1245/s10434-013-3197-x
Predictors of responses to immune checkpoint blockade in advanced melanoma
2017 · Nature Communications · 200 citations
https://doi.org/10.1038/s41467-017-00608-2
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
2020 · npj Breast Cancer · 198 citations
https://doi.org/10.1038/s41523-020-0156-0
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
2023 · Journal of Clinical Oncology · 68 citations
https://doi.org/10.1200/jco.22.02746
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
2022 · Nature Communications · 51 citations
https://doi.org/10.1038/s41467-022-31668-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat